Developer docs
API playgroundTry for free, no card

Search company profiles

Oncomatryx

Full company profile

uuid0000sar

Namestring
Oncomatryx
Legal namestring
ONCOMATRYX BIOPHARMA S.A.
Websiteurl
oncomatryx.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Oncomatryx Biopharma S.A. is a privately held, clinical-stage biopharmaceutical company headquartered in Derio, Spain (Bizkaia Technology Park), with additional R&D operations in Zamudio and San Sebastián (Basque Country, Spain) and Research Triangle Park, North Carolina (via subsidiary Nelum). Founded in 2009–2010 by Dr. Laureano Simón around the discovery that Cancer-Associated Fibroblasts (CAFs) in the tumor stroma drive invasion, drug resistance, and immunosuppression, the company develops a proprietary Antibody-Drug Conjugate (ADC) platform targeting the tumor microenvironment rather than tumor cells directly. The platform integrates three core technology layers: FAP-targeting antibodies with sub-nanomolar affinity, synthetic cytolysin payloads (low molecular weight tubulin polymerization inhibitors that avoid Pgp-mediated multi-drug resistance, acquired via Tube Pharmaceuticals GmbH in 2023), and a proprietary conjugation chemistry designed for bloodstream stability. Lead asset OMTX705 (anti-FAP) is in Phase Ib/2 clinical trials across pancreatic, microsatellite-stable colorectal, NSCLC, and sarcoma indications, with 95 patients dosed and no dose-limiting toxicity observed to date; preclinical assets OMTX703 (anti-endoglin) and OMTX707 (TME-targeting) and a companion diagnostic InvaScan (anti-COL11A1) round out the pipeline.

The company operates a capital-intensive biotech business model. Direct revenues are limited to recurring licensing and co-development income from unnamed international biopharmaceutical partners and non-dilutive European Innovation Council grant funding, with no commercial product sales. Its go-to-market is enterprise-focused: it runs clinical trials directly through a network of seven hospitals in Spain and the USA and pursues licensing and co-development agreements with larger pharmaceutical companies. Capital is sourced primarily from Spanish public investors — CDTI through the Innvierte program, Basque Government and Ekarpen, Kutxa Fundazioa, BBK, and the EIC Accelerator — alongside private family offices, with over €100M raised across rounds in 2015 (€4.5M), 2022 (€15M), 2025 (€25M plus €12.5M EIC), and 2026 (€58M). A March 2026 raise is explicitly financing Oncomatryx's transition into an integrated biopharmaceutical company, including a new Fill & Finish manufacturing plant in Gipuzkoa.

Short descriptiontext

Oncomatryx is a Spain-based clinical-stage biopharmaceutical company developing antibody-drug conjugates that target Cancer-Associated Fibroblasts in the tumor microenvironment, with lead candidate OMTX705 in Phase Ib/2 trials for metastatic solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDerio, Spain
HQ citystring
Derio
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, tumor microenvironment therapeutics, oncology biopharmaceuticals, targeted cancer therapy, companion diagnostics
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing Agreements
TypeLicensing Royalties
Description

Oncomatryx generates recurring revenues from licensing agreements with international biopharmaceutical companies. The company licenses its technology and drug candidates to larger pharmaceutical partners.

oncomatryx.com
2Strategic Co-development Partnerships
TypeLicensing Royalties
Description

Partnerships with pharmaceutical companies for co-development of ADC candidates, including funding contributions and milestone payments.

oncomatryx.com
3EIC Accelerator Funding
TypeManaged Services
Description

Non-dilutive funding from European Innovation Council: €2.5 million grant plus €10 million equity investment in upcoming financing round.

oncomatryx.com
4Future Drug Commercialization
TypeOne Time License
Description

Plans to commercialize approved drug candidates upon successful clinical trials and regulatory approval.

oncomatryx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1InvaScan (DMTXinvaScan)
Description

Immunohistochemical tissue staining system for diagnosis and prognosis of invasive tumors using monoclonal antibody detecting Collagen XI-α1

oncomatryx.com
+4 more records
Core offering1 text field

Oncomatryx develops antibody-drug conjugates (ADCs) that target the tumor microenvironment—specifically Cancer-Associated Fibroblasts (CAFs)—rather than tumor cells directly. Its lead candidate OMTX705 (anti-FAP ADC) is in Phase 1/2 trials for metastatic solid tumors (pancreatic, colorectal, lung, sarcomas), supported by preclinical assets OMTX703 and OMTX707 and companion diagnostic tools such as InvaScan. Revenue is generated through licensing/co-development with biopharmaceutical partners, with future commercialization planned post-approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% tumor growth inhibition and complete regression in PDX models of pancreatic, gastric, ovarian, triple-negative breast, and lung cancers
+3 more records
Product overview1 text field

Oncomatryx is a clinical-stage biopharmaceutical company pioneering Quantum Immunotherapy through a proprietary ADC (Antibody-Drug Conjugate) platform. The company's portfolio centers on three ADC candidates—OMTX705 (Phase 1/2, anti-FAP for multiple solid tumors), OMTX703 (preclinical, anti-endoglin for gastric cancer and sarcomas), and OMTX707 (preclinical, tumor microenvironment-targeting)—alongside companion diagnostic products including InvaScan for detecting COL11A1 in invasive tumors. The integrated platform combines selective tumor microenvironment-targeting antibodies with synthetic cytolysin payloads and stable conjugation technology. The company also operates AI-driven research programs including IA-CLINIC for automated clinical reports and 3DTRYX for 3D biological systems.

Product and service4 records
1OMTX705
CategoryAntibody-Drug Conjugate (ADC) - Clinical Stage
Description

First-in-class anti-FAP (Fibroblast Activation Protein) antibody-drug conjugate targeting cancer-associated fibroblasts in the tumor microenvironment. In Phase 1/2 clinical trials for pancreatic cancer (PDAC), microsatellite-stable colorectal cancer (MSS-CRC), non-small cell lung cancer, and sarcomas.

2OMTX703
CategoryAntibody-Drug Conjugate (ADC) - Preclinical
Description

Anti-endoglin (ENG) antibody-drug conjugate in preclinical development for the treatment of gastric cancer, Ewing sarcoma, and uveal melanoma.

3OMTX707
CategoryAntibody-Drug Conjugate (ADC) - Preclinical
Description

ADC product candidate targeting the tumor microenvironment (TME:CYT), in development for the treatment of sarcomas and fibrosis.

4InvaScan (DMTX Invascan)
CategoryCompanion Diagnostic
Description

Immunohistochemistry-based companion diagnostic for detecting Collagen XI-α1 (COL11A1) in tissue biopsy samples to diagnose and prognose invasive tumors including colon, pancreatic, kidney, breast, ovarian, head and neck, lung, and bladder cancers.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-18
Description

Acquired Tube Pharmaceuticals GmbH for multimillion euros, consolidating decade-long alliance. Acquired Cytolysin toxic payload portfolio and cutting-edge technology. Dr. Wolfgang Richter joined Oncomatryx to lead chemistry efforts. Tube had 15+ years experience in novel ADC payload generation.

2University of Stuttgart
Strategic tierMinorTypeStrategic or Co-development Partner
Description

European academic collaboration in ADC development. Professor Roland E. Kontermann (Subdirector, Institute of Biomedical Engineering) serves on Scientific Advisory Board.

oncomatryx.com
3University of Torino
Strategic tierMinorTypeStrategic or Co-development Partner
Description

European academic collaboration. Professor Franco Dosio (Emeritus, Department of Pharmaceutical Sciences) serves on Scientific Advisory Board.

oncomatryx.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Basque biomedical research center for cancer research and ADC development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Spanish National Cancer Research Center for oncology research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

US academic collaboration in ADC research and development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with leading US cancer center for ADC clinical development.

8Hospitals in Spain and USA (Clinical Trial Sites)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Seven hospitals conducting Phase 1 clinical trials for OMTX705 in Spain and USA. Onkologikoa (Osakidetza) participating under Basque Government collaboration.

oncomatryx.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German clinical-stage biotech developing ADCs with proprietary amanitin payloads, analogous to Oncomatryx's novel payload approach with cytolysins. Both are European ADC platform companies with proprietary payload technologies and lead assets in Phase 1/2 oncology trials.

TypeDirect peer
Description

Clinical-stage ADC company developing pyrrolobenzodiazepine-based antibody-drug conjugates for hematologic and solid tumors. Directly comparable as a focused ADC pure-play with multiple clinical-stage assets and platform payload conjugation technology.

TypeDirect peer
Description

Clinical-stage ADC company with proprietary Dolasynthen and Immunosynthen platforms targeting oncology. Comparable as an ADC-focused biotech developing differentiated linker/payload systems against solid tumor indications.

TypeBroad incumbent
Description

Pioneer in ADC technology with multiple approved and clinical-stage assets including ELAHERE (mirvetuximab), now part of AbbVie. Comparable as an ADC-focused oncology company with proprietary maytansinoid payload and conjugation chemistry used in solid tumor indications.

TypeBroad incumbent
Description

Japanese pharmaceutical leader behind the DXd ADC technology platform used in Enhertu and Datroway, with extensive ADC pipeline in oncology. Comparable as an established ADC innovator targeting solid tumors with proprietary payload and conjugation technology.

TypeEmerging player
Description

Clinical-stage ADC and immuno-oncology biotech with multiple ADC candidates in early-stage trials for solid tumors. Comparable as an emerging ADC company with platform technology focused on tumor-microenvironment and immune-related targets.

TypeEmerging player
Description

Clinical-stage biotech developing conditionally activated Probody ADCs and other masked therapeutics for oncology. Comparable as an emerging ADC platform company with multiple solid tumor candidates in early clinical development.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing ADCs with immune-stimulating Boltbody technology. Comparable as an emerging ADC platform company combining tumor targeting with immune stimulation for solid tumors.

TypeBroad incumbent
Description

Major pharmaceutical company with the Seagen-acquired ADC platform producing approved ADCs like Adcetris and Padcev. Comparable as an established ADC player with proprietary payload technology and multiple oncology programs.

TypeEmerging player
Description

Clinical-stage biotech developing ADCs and immuno-oncology therapeutics for solid tumors, with strategic partnerships with major pharma. Comparable as a European-headquartered ADC company with platform technology targeting multiple solid tumor indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncomatryx

Oncology Biopharmaceuticalsoncomatryx.com

Oncomatryx is a Spain-based clinical-stage biopharmaceutical company developing antibody-drug conjugates that target Cancer-Associated Fibroblasts in the tumor microenvironment, with lead candidate OMTX705 in Phase Ib/2 trials for metastatic solid tumors.

What Oncomatryx does

Oncomatryx Biopharma S.A. is a privately held, clinical-stage biopharmaceutical company headquartered in Derio, Spain (Bizkaia Technology Park), with additional R&D operations in Zamudio and San Sebastián (Basque Country, Spain) and Research Triangle Park, North Carolina (via subsidiary Nelum). Founded in 2009–2010 by Dr. Laureano Simón around the discovery that Cancer-Associated Fibroblasts (CAFs) in the tumor stroma drive invasion, drug resistance, and immunosuppression, the company develops a proprietary Antibody-Drug Conjugate (ADC) platform targeting the tumor microenvironment rather than tumor cells directly. The platform integrates three core technology layers: FAP-targeting antibodies with sub-nanomolar affinity, synthetic cytolysin payloads (low molecular weight tubulin polymerization inhibitors that avoid Pgp-mediated multi-drug resistance, acquired via Tube Pharmaceuticals GmbH in 2023), and a proprietary conjugation chemistry designed for bloodstream stability. Lead asset OMTX705 (anti-FAP) is in Phase Ib/2 clinical trials across pancreatic, microsatellite-stable colorectal, NSCLC, and sarcoma indications, with 95 patients dosed and no dose-limiting toxicity observed to date; preclinical assets OMTX703 (anti-endoglin) and OMTX707 (TME-targeting) and a companion diagnostic InvaScan (anti-COL11A1) round out the pipeline.

The company operates a capital-intensive biotech business model. Direct revenues are limited to recurring licensing and co-development income from unnamed international biopharmaceutical partners and non-dilutive European Innovation Council grant funding, with no commercial product sales. Its go-to-market is enterprise-focused: it runs clinical trials directly through a network of seven hospitals in Spain and the USA and pursues licensing and co-development agreements with larger pharmaceutical companies. Capital is sourced primarily from Spanish public investors — CDTI through the Innvierte program, Basque Government and Ekarpen, Kutxa Fundazioa, BBK, and the EIC Accelerator — alongside private family offices, with over €100M raised across rounds in 2015 (€4.5M), 2022 (€15M), 2025 (€25M plus €12.5M EIC), and 2026 (€58M). A March 2026 raise is explicitly financing Oncomatryx's transition into an integrated biopharmaceutical company, including a new Fill & Finish manufacturing plant in Gipuzkoa.

Oncomatryx firmographics

Firmographics
Name
Oncomatryx
Legal name
ONCOMATRYX BIOPHARMA S.A.
Website
https://oncomatryx.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Oncomatryx is a Spain-based clinical-stage biopharmaceutical company developing antibody-drug conjugates that target Cancer-Associated Fibroblasts in the tumor microenvironment, with lead candidate OMTX705 in Phase Ib/2 trials for metastatic solid tumors.
Ownership category
akta.pro rank

Oncomatryx industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibody-drug conjugates
  • Tumor microenvironment therapeutics
  • Oncology biopharmaceuticals
  • Targeted cancer therapy
  • Companion diagnostics

Where Oncomatryx is headquartered

Location

Headquarters

HQ city
Derio
HQ country
Spain
HQ region
Europe

Offices4 records

Markets served

Oncomatryx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing Agreements: Oncomatryx generates recurring revenues from licensing agreements with international biopharmaceutical companies. The company licenses its technology and drug candidates to larger pharmaceutical partners.
  2. Strategic Co-development Partnerships: Partnerships with pharmaceutical companies for co-development of ADC candidates, including funding contributions and milestone payments.
  3. EIC Accelerator Funding: Non-dilutive funding from European Innovation Council: €2.5 million grant plus €10 million equity investment in upcoming financing round.
  4. Future Drug Commercialization: Plans to commercialize approved drug candidates upon successful clinical trials and regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Oncomatryx product offering

Product offering

Core offering

Oncomatryx develops antibody-drug conjugates (ADCs) that target the tumor microenvironment—specifically Cancer-Associated Fibroblasts (CAFs)—rather than tumor cells directly. Its lead candidate OMTX705 (anti-FAP ADC) is in Phase 1/2 trials for metastatic solid tumors (pancreatic, colorectal, lung, sarcomas), supported by preclinical assets OMTX703 and OMTX707 and companion diagnostic tools such as InvaScan. Revenue is generated through licensing/co-development with biopharmaceutical partners, with future commercialization planned post-approval.

Product overview

Oncomatryx is a clinical-stage biopharmaceutical company pioneering Quantum Immunotherapy through a proprietary ADC (Antibody-Drug Conjugate) platform. The company's portfolio centers on three ADC candidates—OMTX705 (Phase 1/2, anti-FAP for multiple solid tumors), OMTX703 (preclinical, anti-endoglin for gastric cancer and sarcomas), and OMTX707 (preclinical, tumor microenvironment-targeting)—alongside companion diagnostic products including InvaScan for detecting COL11A1 in invasive tumors. The integrated platform combines selective tumor microenvironment-targeting antibodies with synthetic cytolysin payloads and stable conjugation technology. The company also operates AI-driven research programs including IA-CLINIC for automated clinical reports and 3DTRYX for 3D biological systems.

Differentiator

Problem solved

Functional benefit

Brands

  • InvaScan (DMTXinvaScan): Immunohistochemical tissue staining system for diagnosis and prognosis of invasive tumors using monoclonal antibody detecting Collagen XI-α1
  • OMTX705
  • OMTX703
  • OMTX707
  • Quantum ADCs

Products and services

  • OMTX705 First-in-class anti-FAP (Fibroblast Activation Protein) antibody-drug conjugate targeting cancer-associated fibroblasts in the tumor microenvironment. In Phase 1/2 clinical trials for pancreatic cancer (PDAC), microsatellite-stable colorectal cancer (MSS-CRC), non-small cell lung cancer, and sarcomas.
  • OMTX703 Anti-endoglin (ENG) antibody-drug conjugate in preclinical development for the treatment of gastric cancer, Ewing sarcoma, and uveal melanoma.
  • OMTX707 ADC product candidate targeting the tumor microenvironment (TME:CYT), in development for the treatment of sarcomas and fibrosis.
  • InvaScan (DMTX Invascan) Immunohistochemistry-based companion diagnostic for detecting Collagen XI-α1 (COL11A1) in tissue biopsy samples to diagnose and prognose invasive tumors including colon, pancreatic, kidney, breast, ovarian, head and neck, lung, and bladder cancers.

Quantifiable outcome

  • 100% tumor growth inhibition and complete regression in PDX models of pancreatic, gastric, ovarian, triple-negative breast, and lung cancers
  • +3 more outcomes

Companies that use Oncomatryx

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Oncomatryx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Oncomatryx partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Tube Pharmaceuticals GmbHcoreStrategic or Co-development Partner · 18 May 2023Acquired Tube Pharmaceuticals GmbH for multimillion euros, consolidating decade-long alliance. Acquired Cytolysin toxic payload portfolio and cutting-edge technology. Dr. Wolfgang Richter joined Oncomatryx to lead chemistry efforts. Tube had 15+ years experience in novel ADC payload generation.
  • University of StuttgartminorStrategic or Co-development PartnerEuropean academic collaboration in ADC development. Professor Roland E. Kontermann (Subdirector, Institute of Biomedical Engineering) serves on Scientific Advisory Board.
  • University of TorinominorStrategic or Co-development PartnerEuropean academic collaboration. Professor Franco Dosio (Emeritus, Department of Pharmaceutical Sciences) serves on Scientific Advisory Board.
  • CIC-BioguneminorStrategic or Co-development PartnerCollaboration with Basque biomedical research center for cancer research and ADC development.
  • CNIO (Centro Nacional de Investigaciones Oncológicas)minorStrategic or Co-development PartnerCollaboration with Spanish National Cancer Research Center for oncology research.
  • Harvard UniversityminorStrategic or Co-development PartnerUS academic collaboration in ADC research and development.
  • MD Anderson Cancer CenterminorStrategic or Co-development PartnerCollaboration with leading US cancer center for ADC clinical development.
  • Hospitals in Spain and USA (Clinical Trial Sites)coreStrategic or Co-development PartnerSeven hospitals conducting Phase 1 clinical trials for OMTX705 in Spain and USA. Onkologikoa (Osakidetza) participating under Basque Government collaboration.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Oncomatryx competitors and assessment

Company assessment

Direct peers

  • Heidelberg Pharma: German clinical-stage biotech developing ADCs with proprietary amanitin payloads, analogous to Oncomatryx's novel payload approach with cytolysins. Both are European ADC platform companies with proprietary payload technologies and lead assets in Phase 1/2 oncology trials.
  • ADC Therapeutics: Clinical-stage ADC company developing pyrrolobenzodiazepine-based antibody-drug conjugates for hematologic and solid tumors. Directly comparable as a focused ADC pure-play with multiple clinical-stage assets and platform payload conjugation technology.
  • Mersana Therapeutics: Clinical-stage ADC company with proprietary Dolasynthen and Immunosynthen platforms targeting oncology. Comparable as an ADC-focused biotech developing differentiated linker/payload systems against solid tumor indications.

Broad incumbents

  • ImmunoGen (AbbVie): Pioneer in ADC technology with multiple approved and clinical-stage assets including ELAHERE (mirvetuximab), now part of AbbVie. Comparable as an ADC-focused oncology company with proprietary maytansinoid payload and conjugation chemistry used in solid tumor indications.
  • Daiichi Sankyo: Japanese pharmaceutical leader behind the DXd ADC technology platform used in Enhertu and Datroway, with extensive ADC pipeline in oncology. Comparable as an established ADC innovator targeting solid tumors with proprietary payload and conjugation technology.
  • Pfizer (Seagen): Major pharmaceutical company with the Seagen-acquired ADC platform producing approved ADCs like Adcetris and Padcev. Comparable as an established ADC player with proprietary payload technology and multiple oncology programs.

Emerging players

  • Pyxis Oncology: Clinical-stage ADC and immuno-oncology biotech with multiple ADC candidates in early-stage trials for solid tumors. Comparable as an emerging ADC company with platform technology focused on tumor-microenvironment and immune-related targets.
  • CytomX Therapeutics: Clinical-stage biotech developing conditionally activated Probody ADCs and other masked therapeutics for oncology. Comparable as an emerging ADC platform company with multiple solid tumor candidates in early clinical development.
  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing ADCs with immune-stimulating Boltbody technology. Comparable as an emerging ADC platform company combining tumor targeting with immune stimulation for solid tumors.
  • Oxford BioTherapeutics: Clinical-stage biotech developing ADCs and immuno-oncology therapeutics for solid tumors, with strategic partnerships with major pharma. Comparable as a European-headquartered ADC company with platform technology targeting multiple solid tumor indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Oncomatryx social profiles

Digital presence

Oncomatryx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncomatryx leadership team

Management profile

Number of profiles

Profiles6 records

Oncomatryx subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Oncomatryx funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncomatryx M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncomatryx

What does Oncomatryx do?

Oncomatryx develops antibody-drug conjugates (ADCs) that target the tumor microenvironment—specifically Cancer-Associated Fibroblasts (CAFs)—rather than tumor cells directly. Its lead candidate OMTX705 (anti-FAP ADC) is in Phase 1/2 trials for metastatic solid tumors (pancreatic, colorectal, lung, sarcomas), supported by preclinical assets OMTX703 and OMTX707 and companion diagnostic tools such as InvaScan. Revenue is generated through licensing/co-development with biopharmaceutical partners, with future commercialization planned post-approval.

Is Oncomatryx a public or private company?

Oncomatryx is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oncomatryx founded?

Oncomatryx was founded in 2010. It employs 11 to 50 people.

Where is Oncomatryx based?

Oncomatryx is headquartered in Derio, Spain, in the Europe region.

How does Oncomatryx make money?

Four revenue lines are on record. Licensing Agreements are the primary driver. The others are strategic Co-development Partnerships, EIC Accelerator Funding and future Drug Commercialization.

Who are Oncomatryx's main competitors?

Direct peers on record are Heidelberg Pharma, ADC Therapeutics and Mersana Therapeutics. Broad incumbents are ImmunoGen (AbbVie), Daiichi Sankyo and Pfizer (Seagen). Emerging players are Pyxis Oncology, CytomX Therapeutics, Bolt Biotherapeutics and Oxford BioTherapeutics.

Does Oncomatryx have an API?

No public API is recorded for Oncomatryx.

What industry is Oncomatryx in?

Oncomatryx's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageAntibody Designed by Spanish Biopharma Oncomatryx Shows That Attacking the Tumor Environment Also Kills Cancer CellsA study in Science Advances shows that OMTX305, an antibody from Oncomatryx, destroyed fibroblasts in tumor tissue from 15 lung and ovarian cancer patients, reducing their area from 38% to 24% in three days. The antibody also increased death of nearby cancer cells, supporting the company's microenvironment-targeting approach.BioWorldOncomatryx describes new endoglin-targeting ADCsOncomatryx SL has patented antibody-drug conjugates comprising antibodies targeting endoglin covalently linked to therapeutic drugs. The company states these ADCs are potentially useful for the treatment of cancer.WebcapitalriesgoCDTI Innvierte destina en marzo más de €113M 6 nuevas coinversiones en capital riesgo y 2 vehículos de inversiónCDTI Innovación closed six coinvestment deals in March totaling €33.06 million, including two strategic investments in oncomatryx and XOOPLE. It also committed €80.56 million to two investment funds, bringing total commitments since January 2026 to €141.6 million.Pulse 2.0Oncomatryx: $67 Million Raised To Advance Quantum ADC Cancer TherapiesOncomatryx has raised $67 million in a financing round backed by Spanish public institutions and private investors to advance its next-generation Quantum ADC cancer therapies into clinical trials. The funding round included a $28 million strategic investment from CDTI, $18 million from Kutxa Fundazioa, $12 million from the Basque Government alongside Ekarpen VC, and $2 million from BBK. The capital will support the company's lead candidate OMTX705 and additional programs including OMTX105, with Phase Ib-II results for OMTX705 expected at major oncology conferences in 2026.VentureBeatONCOMATRYX Raises $67 Million to Foster the Clinical Development of Its Quantum ADCs in SpainONCOMATRYX, a Spanish biopharmaceutical company developing Quantum ADCs for metastatic solid tumors, has raised $67 million in a funding round. The round was led by institutional investors including the Spanish Government through CDTI ($28 million), Kutxa Fundazioa ($18 million), Basque Government and Ekarpen VC ($12 million), BBK ($2 million), and Spanish and international private investors. The funding will support clinical development of lead candidate OMTX705 and advance OMTX105 and other Quantum ADCs into clinical trials.OncomatryxKutxa Fundazioa, the Basque Government, and the Spanish Government are driving Oncomatryx’s transformation into a biopharmaceutical company – OncomatryxOncomatryx, a Basque biotech company, has completed a 58 million euro capital increase backed by multiple institutional investors including the Spanish Government (24.3M€ through Innvierte/CDTI), Kutxa Fundazioa (15M€), the Basque Government and Ekarpen (10.5M€), and BBK (2M€), alongside other private investors. The funding will support the company's transition into an integrated biopharmaceutical firm, advance its lead drug OMTX705 through Phase 1B-2A clinical trials, and establish a Fill & Finish manufacturing plant for high-potency oncology drugs in Gipuzkoa. The Spanish and Basque governments describe the investment as part of a public-private partnership to strengthen Spain's position in biotechnology and advanced oncology therapies.Diariovasco«Oncomatryx es un proyecto interesante que aporta valor al territorio, por eso invertimos»Kutxa Fundazioa reaffirmed its investment in Oncomatryx, citing the project's potential to add value to the territory and its aspiration to become a sector leader. The foundation has been part of Oncomatryx's shareholder base since the company's early stages.Empresas de Capital Riesgo en EspaKutxa Fundazioa, together with the Basque and Spanish governments, support Oncomatryx’s transformation into a biopharmaceutical companyOncomatryx Biopharma, a Basque biotech company, successfully completed a €58 million capital increase to transition into a biopharmaceutical company, supported by public and private investors including Kutxa Fundazioa, the Basque Government, and the Spanish Ministry of Science, Innovation and Universities. The investment aims to develop a manufacturing plant in Gipuzkoa for high-potency oncology drugs and enhance Europe's biological medicines capacity.